Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 250

The DOI matches its Crossref record.

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Open access
Moskowitz, Craig H., Walewski, Jan, Nademanee, Auayporn, Masszi, Tamas, Agura, Edward, Holowiecki, Jerzy, Abidi, Muneer H., Chen, Andy I., Stiff, Patrick, Viviani, Simonetta, Bachanova, Veronika, Sureda, Anna, McClendon, Teresa, Lee, Connie, Lisano, Julie, Sweetenham, John · 2018 · Blood

Abstract

Key Points: Early consolidation with BV improves 5-year PFS vs best supportive care and reduces the need for subsequent therapy. At 5-year follow-up, BV shows long-term tolerability, with peripheral neuropathy continuing to improve and/or resolve.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2018-07-861641

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 250

Metadata

Authors
Moskowitz, C. H., Walewski, J., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Viviani, S., Bachanova, V., Sureda, A., McClendon, T., Lee, C., Lisano, J., & Sweetenham, J.
Venue
Blood
Published
2018-12-20
Volume
132
Issue
25
Pages
2639-2642
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2892881565
Cited by
250
References
0
FWCI
17.03
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. https://app.cochat.ai/papers/10.1182/blood-2018-07-861641
The paper
Moskowitz, C. H., Walewski, J., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Viviani, S., Bachanova, V., Sureda, A., McClendon, T., Lee, C., Lisano, J., & Sweetenham, J. (2018). Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. https://doi.org/10.1182/blood-2018-07-861641

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.